AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at the recent Annual Meeting of the American Association of Immunologists held May 3-7, 2025, in Honolulu, HI.

The paper, titled “Systemic Infusion of dsRNA (Rintatolimod) plus IFN Promotes Selective Influx of CTLs (but not Treg) into the TME — Counteracting Chemokine Heterogeneity of the TME,” discussed the unique two-level selectivity of action of Ampligen when used as a part of chemokine modulation and combined with PD-1 blockade or chemotherapy. Dr. Kalinski discussed the preclinical data and data from recently completed clinical trials showing the ability of Ampligen to selectively induce the desirable CTL-attracting chemokines, but not the counterproductive Treg-attracting chemokines, which differentiated it from poly-I:C. The second level of selectivity was the preferential activation of cancer tissues, rather than healthy tissues. The mechanistic data discussed by Dr. Kalinski indicate that the selectivity of Ampligen’s impact on the tumor microenvironment result from its avoidance of helicase-dependent activation of NFkB. This allows Ampligen to avoid the induction of TNFα and other NFkB-dependent undesirable inflammatory and suppressive factors, which are commonly induced by poly-I:C and other TLR ligands, and to focus its impact on the tumor tissues, which display elevated levels of endogenous NFkB.

AIM CEO Thomas K. Equels commented: “These findings and Dr. Kalinski’s analysis further support our belief in the potential of Ampligen as a powerful therapeutic for unmet medical needs, including deadly cancers.”

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen^® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in oncology. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com